The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A
Open accessAbstract
SB-277011-A (trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolininecarboxamide), is a brain-penetrant, high-affinity, and selective dopamine D(3) receptor antagonist. Radioligand-binding experiments in Chinese hamster ovary (CHO) cells transfected with human dopamine D(3) or D(2 long) (hD(3), hD(2)) receptors showed SB-277011-A to have high affinity for the hD(3) receptor (pK(i) = 7.95) with 100-fold selectivity over the hD(2) receptor and over 66 other receptors, enzymes, and ion channels. Similar radioligand-binding data for SB-277011-A were obtained from CHO cells transfected with rat dopamine D(3) or D(2). In the microphysiometer functional assay, SB-277011-A antagonized quinpirole-induced increases in acidification in CHO cells overexpressing the hD(3) receptor (pK(b) = 8.3) and was 80-fold selective over hD(2) receptors. Central nervous system penetration studies showed that SB-277011-A readily entered the brain. In in vivo microdialysis studies, SB-277011-A (2. 8 mg/kg p.o.) reversed the quinelorane-induced reduction of dopamine efflux in the nucleus accumbens but not striatum, a regional selectivity consistent with the distribution of the dopamine D(3) receptor in rat brain. SB-277011-A (2-42.3 mg/kg p.o.) did not affect spontaneous locomotion, or stimulant-induced hyperlocomotion. SB-277011-A (4.1-42.2 mg/kg p.o.) did not reverse prepulse inhibition deficits in apomorphine- or quinpirole-treated rats, but did significantly reverse the prepulse inhibition deficit in isolation-reared rats at a dose of 3 mg/kg p.o. SB-277011-A (2.5-78. 8 mg/kg p.o.) was noncataleptogenic and did not raise plasma prolactin levels. Thus, dopamine D(3) receptor blockade produces few of the behavioral effects characteristic of nonselective dopamine receptor antagonists. The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
ARUNLAKSHANA, O., & SCHILD, H. O. (1959) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1959.tb00928.x · Cited by 3,938
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Allelic discrimination using fluorogenic probes and the 5′ nuclease assay
Livak, K. J. (1999) · Genetic Analysis: Biomolecular Engineering · doi:10.1016/s1050-3862(98)00019-9 · Cited by 1,379
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A., Wermuth, C. G., Schwartz, J.-C., Everitt, B. J., & Sokoloff, P. (1999) · Nature · doi:10.1038/22560 · Cited by 565
SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist
KENNETT, G. A., WOOD, M. D., BRIGHT, F., TRAIL, B., RILEY, G., HOLLAND, V., AVENELL, K. Y., STEAN, T., UPTON, N., BROMIDGE, S., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00038-5 · Cited by 523
Self-citationA targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.
Accili, D., Fishburn, C. S., Drago, J., Steiner, H., Lachowicz, J. E., Park, B. H., Gauda, E. B., Lee, E. J., Cool, M. H., Sibley, D. R., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1945 · Cited by 468
Modulation of Cocaine Self-Administration in the Rat Through D-3 Dopamine Receptors
Caine, S. B., & Koob, G. F. (1993) · Science · doi:10.1126/science.8099761 · Cited by 454
Gurevich, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00066-9 · Cited by 431
Cited by
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., & Sokoloff, P. (2003) · Nature Medicine · doi:10.1038/nm875 · Cited by 383
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Dopamine D3Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
Vorel, S. R., Ashby, C. R., Paul, M., Liu, X., Hayes, R., Hagan, J. J., Middlemiss, D. N., Stemp, G., & Gardner, E. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09595.2002 · Cited by 269
Self-citationCaine, S. B., Negus, S. S., Mello, N. K., Patel, S., Bristow, L., Kulagowski, J., Vallone, D., Saiardi, A., & Borrelli, E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02977.2002 · Cited by 234
Metadata
- Authors
- Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., Hadley, M. S., Hunter, A. J., Jeffrey, P., Jewitt, F., Johnson, C. N., Jones, D. N. C., Medhurst, A. D., Middlemiss, D. N., Nash, D. J., Riley, G. J., Routledge, C., Stemp, G., Thewlis, K. M., Trail, B., Vong, A. K. K., & Hagan, J. J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 294
- Issue
- 3
- Pages
- 1154-1165
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2155207556
- Cited by
- 287
- References
- 39
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A. https://app.cochat.ai/papers/10.1016/s0022-3565(24)39184-0
- The paper
- Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., Hadley, M. S., Hunter, A. J., Jeffrey, P., Jewitt, F., Johnson, C. N., Jones, D. N. C., Medhurst, A. D., Middlemiss, D. N., Nash, D. J., . . . Hagan, J. J. (2000). Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)39184-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.